PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:
62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2, 2026 in Milan, Italy
Breakthrough T1D® Clinical & Research Congress 2026 (CRC 2026), taking place October 9–11, 2026 in Philadelphia, Pennsylvania
Both presentations will highlight CNTY-813, Century's iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes.
EASD 2026 Presentation Details
Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies
Format: Oral Presentation
Presenter: Grant Welstead, PhD, SVP, Head of Research, Century Therapeutics
Session: OP 39 – Beta cells on demand: stem cells to beta cell therapy
Presentation Number: 225
Date/Time: Friday, October 2, 2026, 10:00–11:00 AM CEST, Paris Hall
CRC 2026 Presentation Details
Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies
Format: Oral Presentation
Presenter: Leonardo Velazco-Cruz, PhD, Islet Process Science
Session: 0300 - ORALS 01: Cell Therapy Science & Clinical
Presentation Number: 341
Date/Time: Friday, October 9, 2026, 3:50-4:50 PM EDT, Hall 1
Additional information about the EASD 2026 Annual Meeting is available on the EASD website, and additional information about the CRC 2026 Congress is available on the CRC website.
Both presentations will be made available on Century's website following the session on its presentations tab: Science | Century Therapeutics.
About CNTY-813
CNTY-813 is Century's potential iPSC-derived islet replacement therapy for T1D. CNTY-813 is engineered with Allo-Evasion™ 5.0, Century's proprietary immune evasion technology, which is designed to enable durable engraftment without chronic systemic immunosuppression, the central unresolved limitation of every currently approved or late-stage cell therapy approach to T1D. Preclinical data demonstrated robust glucose-responsive function, favorable pre-clinical safety profile, scalable and reproducible manufacturing, and immune protection under alloimmune pressure. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026.